Researchers at Georgia Tech have built a cell-free biocatalyst that converts simple one-carbon feedstocks into the amino acids serine and glycine at roughly 97% of the maximum theoretical yield. The system, which uses formate and bicarbonate as inputs, sidesteps a fundamental limitation of traditional fermentation: because no living cells are involved, zero carbon is lost to cell growth. The result is a carbon-negative production method for molecules that serve as building blocks across food, pharmaceutical, and chemical industries.
How Nine Genes Hit 97% Yield
The core innovation is a thermophilic enzyme cascade expressed inside a mesophilic E. coli lysate. The team assembled a 9-gene thermophilic pathway that channels formate and bicarbonate through a sequence of reactions ending in serine and glycine. After a 16-hour gene expression step, during which cell-free expression of a reporter protein reaches saturation, the researchers heat-treated the mixture. That step inactivated the background E. coli machinery, preventing host enzymes from siphoning intermediates and cofactors away from the target pathway.
The trick is elegant in its logic. Thermophilic enzymes thrive at temperatures that denature mesophilic proteins. By running the biocatalysis at elevated temperature after expression, the Georgia Tech group effectively silenced competing side reactions while keeping their designed pathway fully active. After optimization, the system achieved approximately 97% of stoichiometric yield for the conversion of formate and bicarbonate to serine and glycine, as reported in a recent study describing the platform. That figure is striking because bioproduction from one-carbon compounds like formate already benefits from reduced energy requirements compared with sugar-based fermentation, and near-complete conversion means almost no feedstock is wasted.
Why Cell-Free Systems Change the Math
Conventional amino acid manufacturing relies on microbial fermentation, where engineered bacteria or yeast consume sugars and excrete the desired product. The problem is that living cells have their own priorities. A significant fraction of the carbon input feeds biomass growth, DNA replication, and maintenance metabolism rather than product formation. In a cell-free system, that diversion disappears. “To our knowledge, it’s the first time anyone has synthesized amino acids in a carbon-negative way using this type of biocatalyst,” a member of the Georgia Tech team noted in an institutional summary of the earlier foundational work, emphasizing that no carbon is sequestered in new cells.
The practical upshot goes beyond yield percentages. Georgia Tech’s system retains catalytic activity even after 200-fold dilution, a sign that the enzyme concentrations needed for production are modest and that the platform could tolerate the kind of volumetric scaling industrial processes demand. Pamela Peralta-Yahya, who leads the group, framed the research question directly: they wondered whether introducing enzymes from thermophilic bacteria could balance the pathway and boost yields. The answer, based on the published data, is yes. By separating the expression and catalysis phases and exploiting temperature to switch off unwanted activities, the team created a controllable, modular production unit.
Building on a Decade of Cell-Free Carbon Fixation
This work did not emerge in isolation. A parallel line of research has been assembling the biochemical toolkit needed to turn CO2 and its derivatives into valuable molecules outside living cells. In 2021, Cai and colleagues demonstrated cell-free chemoenzymatic conversion of CO2 into starch, showing that a carefully orchestrated enzyme network could rival plant metabolism; their Science report provided a proof-of-concept that complex polysaccharides can be synthesized without a genome or a growth cycle. That work established design principles for combining dozens of enzymes in vitro while maintaining flux balance and cofactor availability.
Separately, another team developed a pathway in which methanol and captured CO2 are converted to glycine, serine, and pyruvate in a system that requires no external ATP or NAD(P)H. In this Nature Communications study, the researchers broke a thermodynamic bottleneck by coupling exergonic chemical transformations with enzymatic steps, effectively embedding energy and reducing power into the feedstock itself. The resulting network bypassed the need for cellular energy currencies, simplifying the reactor design and pointing toward self-sufficient synthetic pathways.
Other groups have extended the parts catalog needed for such systems. Engineered carboxylation modules described in Nature Catalysis introduced new-to-nature enzyme activities that improve both natural and synthetic CO2 fixation, expanding the range of carbon skeletons accessible from inorganic carbon. Synthetic anaplerotic modules published in Nature Chemical Biology showed how redesigned reaction networks can directly incorporate CO2 into metabolic intermediates, enabling tailored production of downstream compounds. Together, these advances supply the functional pieces that can be dropped into cell-free platforms like Georgia Tech’s serine–glycine cascade.
A separate study in Chem Catalysis demonstrated cell-free enzymatic L-alanine synthesis from green methanol, highlighting how one-carbon alcohols can also serve as starting points for amino acid production. That work used a multi-enzyme sequence to transform methanol-derived intermediates into a chiral product, and the authors reported robust performance in a bench-scale reactor. With serine, glycine, and alanine now all accessible via cell-free routes, a basic palette of proteinogenic building blocks is emerging from C1 chemistry.
Electrochemistry Meets Enzymes
One of the most promising recent developments couples the biological side of this equation with electrochemistry. A synthetic cell-free pathway known as ReForm, detailed in a Nature Chemical Engineering article, takes formate generated by electrochemical CO2 reduction and upgrades it into useful chemicals through a designed enzyme cascade. The concept is modular: electricity splits CO2 into formate at a cathode, and biology finishes the job. Cell-free systems enable rapid screening of pathway variants and operating conditions, which accelerates the design cycle compared with engineering whole organisms.
That modularity matters because it decouples the carbon capture step from the biosynthesis step. An electrolyzer running on intermittent renewable power can operate whenever electricity is cheap, generating a stockpile of formate or methanol. Downstream, a thermostable enzyme cascade (such as the Georgia Tech serine and glycine pathway) can run continuously or in flexible batches, drawing from that reservoir. This temporal and spatial separation gives process engineers more freedom in plant design, potentially lowering capital costs and improving resilience to fluctuations in power supply.
Cell-free platforms also simplify integration with emerging CO2 capture technologies. Because enzymes can be tuned to tolerate impurities and varying concentrations, they can in principle accept formate or bicarbonate streams derived directly from flue gas scrubbing or direct air capture. The Georgia Tech system’s ability to maintain activity after substantial dilution hints at robustness to such variable inputs. In a future deployment, captured CO2 could be converted electrochemically to formate on-site, then fed into a thermophilic biocatalyst that outputs amino acids ready for downstream purification.
From Lab Bench to Process Scale
Significant challenges remain before carbon-negative amino acid production becomes a commercial reality. Enzyme cost and stability will be central: while thermophilic proteins are inherently more resistant to denaturation, industrial reactors must operate for long periods without frequent catalyst replacement. Cofactor recycling, reactor design, and continuous removal of products to avoid feedback inhibition will all influence economics. Nonetheless, the Georgia Tech work demonstrates that, at least on the level of carbon balance and stoichiometric efficiency, the underlying chemistry is already highly favorable.
Equally important is the question of product portfolio. Serine and glycine are valuable in their own right, feeding into nutraceuticals, pharmaceuticals, and specialty chemicals. But they are also branching points in metabolism. With the right additional enzymes, they can be transformed into a wider array of compounds, from C2 and C3 intermediates to more complex molecules. The same logic that led to a nine-enzyme cascade for two amino acids could, in principle, yield longer synthetic routes that start from formate and end in polymers, solvents, or active pharmaceutical ingredients.
For now, the Georgia Tech system stands as a clear benchmark: nearly complete conversion of C1 inputs into amino acid products, with no carbon diverted to cellular maintenance. Combined with advances in CO2 fixation, methanol upgrading, and electrochemical formate generation, it points toward a new class of manufacturing processes in which carbon-negative chemistry is not an afterthought but a design constraint from the outset. If those processes can be scaled and made cost-competitive, the amino acids in tomorrow’s foods and medicines may trace their origins not to sugar-fed fermenters, but to captured CO2 and a carefully choreographed suite of enzymes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
